Takeda Pharmaceutical Co. entered into a partnership with Schrödinger to create a multitarget research collaboration.
Here's what you should know:
1. The collaboration will attempt to discover drugs in Takeda's key therapeutic areas of interest.
2. Takeda will provide protein crystal structures to Schrödinger for use in its in silico technology platform.
3. Schrödinger will cover all discovery costs, providing Takeda with rights to license the programs from Schrödinger.
4. Takeda will pay up to $170 million per program as well as potential royalties.